openPR Logo
Press release

Surgical Site Infections Pipeline 2024: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Merck Sharp & Dohme LLC, Destiny Pharma Plc, PolyPid Ltd., Durata Therapeutics

01-16-2025 07:41 PM CET | Health & Medicine

Press release from: DelveInsight Business Research

Surgical Site Infections Pipeline 2024: Key Companies, MOA,

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Surgical Site Infections pipeline constitutes 5+ key companies continuously working towards developing 5+ Surgical Site Infections treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Surgical Site Infections Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

"Surgical Site Infections Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Surgical Site Infections Market.

Some of the key takeaways from the Surgical Site Infections Pipeline Report: https://www.delveinsight.com/sample-request/surgical-site-infections-ssi-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Surgical Site Infections treatment therapies with a considerable amount of success over the years.
• Surgical Site Infections companies working in the treatment market are MinaPharm Pharma, Duke Clinical Research, Zurex Pharma, Inc., Merck Sharp & Dohme LLC, Destiny Pharma Plc, PolyPid Ltd., Durata Therapeutics, Lindenhofgruppe AG, Veristat, Inc, and others, are developing therapies for the Surgical Site Infections treatment
• Emerging Surgical Site Infections therapies in the different phases of clinical trials are- Ciprodiazole, DFA-02, ZuraPrep, Ertapenem, XF-73, D-PLEX, Dalbavancin, BACTROBAN® Nasal ong, E-101, and others are expected to have a significant impact on the Surgical Site Infections market in the coming years.
• In January 2023, PolyPid Ltd. provided a positive regulatory update for D-PLEX100 for the prevention of abdominal colorectalsurgical site infections (SSIs). Following a recent type D meeting communication with the US Food and Drug Administration (FDA)on the SHIELD I Phase III data, the Company now has clarity regarding the regulatory pathway toward a potential New DrugApplication (NDA) submission.
• In April 2023, The inaugural randomized clinical trial associated with registry data from the American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP®) indicates that modifying antibiotics prior to pancreatoduodenectomy, commonly referred to as the Whipple procedure, leads to a decrease in the occurrence of surgical site infections (SSIs) among patients undergoing the surgery.
• In April 2022, Mölnlycke expanded in Malaysia by constructing a new surgical glove factory. The company is increasing its manufacturing capacity to ensure that it can continue to satisfy the growing demand for Biogel gloves.

Surgical Site Infections Overview
Surgical Site Infections (SSIs) are infections that occur at the site of a surgical incision or in the surrounding tissue following a surgical procedure. These infections can range from superficial infections involving the skin and subcutaneous tissue to more severe infections affecting deeper layers of tissue, such as muscles and organs.

Get a Free Sample PDF Report to know more about Surgical Site Infections Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/surgical-site-infections-ssi-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Surgical Site Infections Drugs Under Different Phases of Clinical Development Include:
• Ciprodiazole: MinaPharm Pharma
• DFA-02: Duke Clinical Research
• ZuraPrep: Zurex Pharma, Inc.
• Ertapenem: Merck Sharp & Dohme LLC
• XF-73: Destiny Pharma Plc
• D-PLEX: PolyPid Ltd.
• Dalbavancin: Durata Therapeutics
• BACTROBAN® Nasal ong: Lindenhofgruppe AG
• E-101: Veristat, Inc

Surgical Site Infections Route of Administration
Surgical Site Infections pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous

Surgical Site Infections Molecule Type
Surgical Site Infections Products have been categorized under various Molecule types, such as
• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine

Surgical Site Infections Pipeline Therapeutics Assessment
• Surgical Site Infections Assessment by Product Type
• Surgical Site Infections By Stage and Product Type
• Surgical Site Infections Assessment by Route of Administration
• Surgical Site Infections By Stage and Route of Administration
• Surgical Site Infections Assessment by Molecule Type
• Surgical Site Infections by Stage and Molecule Type

DelveInsight's Surgical Site Infections Report covers around 5+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Surgical Site Infections product details are provided in the report. Download the Surgical Site Infections pipeline report to learn more about the emerging Surgical Site Infections therapies
https://www.delveinsight.com/sample-request/surgical-site-infections-ssi-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Surgical Site Infections Therapeutics Market include:
Key companies developing therapies for Surgical Site Infections are - Becton, Dickinson and Company, 3M Company, Biomerieux SA, Getinge Group, and Johnson & Johnson, and others.

Surgical Site Infections Pipeline Analysis:
The Surgical Site Infections pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Surgical Site Infections with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Surgical Site Infections Treatment.
• Surgical Site Infections key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Surgical Site Infections Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Surgical Site Infections market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Surgical Site Infections drugs and therapies
https://www.delveinsight.com/sample-request/surgical-site-infections-ssi-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Surgical Site Infections Pipeline Market Drivers
• Rising number of surgeries and the growing geriatric population, increasing concern about hospital acquired infections along with rising incidences of hospital-acquired infections are some of the important factors that are fueling the Surgical Site Infections Market.

Surgical Site Infections Pipeline Market Barriers
• However, lack of awareness regarding infection control measures, difficulty in identifying the site of infection and other factors are creating obstacles in the Surgical Site Infections Market growth.

Scope of Surgical Site Infections Pipeline Drug Insight
• Coverage: Global
• Key Surgical Site Infections Companies: MinaPharm Pharma, Duke Clinical Research, Zurex Pharma, Inc., Merck Sharp & Dohme LLC, Destiny Pharma Plc, PolyPid Ltd., Durata Therapeutics, Lindenhofgruppe AG, Veristat, Inc, and others
• Key Surgical Site Infections Therapies: Ciprodiazole, DFA-02, ZuraPrep, Ertapenem, XF-73, D-PLEX, Dalbavancin, BACTROBAN® Nasal ong, E-101, and others
• Surgical Site Infections Therapeutic Assessment: Surgical Site Infections current marketed and Surgical Site Infections emerging therapies
• Surgical Site Infections Market Dynamics: Surgical Site Infections market drivers and Surgical Site Infections market barriers

Request for Sample PDF Report for Surgical Site Infections Pipeline Assessment and clinical trials
https://www.delveinsight.com/sample-request/surgical-site-infections-ssi-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Surgical Site Infections Report Introduction
2. Surgical Site Infections Executive Summary
3. Surgical Site Infections Overview
4. Surgical Site Infections- Analytical Perspective In-depth Commercial Assessment
5. Surgical Site Infections Pipeline Therapeutics
6. Surgical Site Infections Late Stage Products (Phase II/III)
7. Surgical Site Infections Mid Stage Products (Phase II)
8. Surgical Site Infections Early Stage Products (Phase I)
9. Surgical Site Infections Preclinical Stage Products
10. Surgical Site Infections Therapeutics Assessment
11. Surgical Site Infections Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Surgical Site Infections Key Companies
14. Surgical Site Infections Key Products
15. Surgical Site Infections Unmet Needs
16 . Surgical Site Infections Market Drivers and Barriers
17. Surgical Site Infections Future Perspectives and Conclusion
18. Surgical Site Infections Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Surgical Site Infections Market https://www.delveinsight.com/report-store/surgical-site-infections-ssi-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Surgical Site Infections Market Insights, Epidemiology, and Market Forecast-2034' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Surgical Site Infections Epidemiology https://www.delveinsight.com/report-store/surgical-site-infection-ssi-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Surgical Site Infections Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:
• Interspinous Spacers Market: https://www.delveinsight.com/report-store/interspinous-spacers-market
• Dengue Fever Market: https://www.delveinsight.com/report-store/dengue-fever-market
• Chronic Hemodialysis Market: https://www.delveinsight.com/report-store/chronic-hemodialysis-market
• Brucellosis Market: https://www.delveinsight.com/report-store/brucellosis-market
• Childhood Atropine For Myopia Progression Market: https://www.delveinsight.com/sample-request/childhood-atropine-for-myopia-progression-market
• Artificial Kidney Market: https://www.delveinsight.com/report-store/artificial-kidney-market
• Cardiac Rhythm Management Devices Market: https://www.delveinsight.com/report-store/cardiac-rhythm-management-devices-market

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Surgical Site Infections Pipeline 2024: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Merck Sharp & Dohme LLC, Destiny Pharma Plc, PolyPid Ltd., Durata Therapeutics here

News-ID: 3818924 • Views:

More Releases from DelveInsight Business Research

Biliary Atresia Market Analysis 2034 - Competitive Landscape, Clinical Trials, Market Size, Medication, Prevalence, Companies by DelveInsight
Biliary Atresia Market Analysis 2034 - Competitive Landscape, Clinical Trials, M …
Biliary Atresia Market Summary The Biliary Atresia market is projected to grow at a steady CAGR of 7.7% between 2024 and 2034, fueled by rising incidence, improved diagnostic methods, and broader adoption of treatment strategies. In 2023, the 7MM recorded approximately 609 new cases, with the US accounting for 56%, EU4 and the UK for 28%, and Japan for 16%. Despite this, therapeutic options remain limited, with surgery, such as the
Sickle Cell Disease Market Analysis 2034 - Competitive Landscape, Market Size, Clinical Research, Therapies, Epidemiology, and Key Players by DelveInsight
Sickle Cell Disease Market Analysis 2034 - Competitive Landscape, Market Size, C …
The Sickle Cell Disease market across the six major markets (6MM) was valued at approximately USD 650 million in 2023. Key players driving this market include Cellectis, Sana Biotechnology, Global Blood Therapeutics, Inc., CSL Behring, Pfizer, Aruvant Sciences, Graphite Bio, Novartis, Agios Pharmaceuticals, Forma Therapeutics, Vertex Pharmaceuticals, Global Blood Therapeutics, Inc., Alfasigma, Novo Nordisk, bluebird bio, ExCellThera, Gamida Cell, KM Biologics/Takeda, Editas Medicine, and others. Request for a Free Sample Report
Impetigo Market Analysis 2034 - Competitive Landscape, Clinical Trials, Market Share, Therapies, Prevalence, and Key Players by DelveInsight
Impetigo Market Analysis 2034 - Competitive Landscape, Clinical Trials, Market S …
DelveInsight, a leading market research and consulting firm, has released its latest report, "Impetigo Treatment Market Insights, Epidemiology, and Market Forecast-2032," providing an in-depth analysis of the Impetigo treatment landscape, epidemiology trends, and emerging market opportunities across the seven major markets (7MM) - the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. The Impetigo market is poised for robust growth as awareness of the disease increases
Allergic Contact Dermatitis Market Poised for Significant Expansion, Driven by Recent FDA Approvals and Emerging Therapies Targeting Specific Immune Pathways | DelveInsight
Allergic Contact Dermatitis Market Poised for Significant Expansion, Driven by R …
The allergic contact dermatitis treatment market is poised for substantial growth, driven by increasing prevalence rates, growing awareness, enhanced diagnostic capabilities, and the emergence of innovative treatment options targeting specific immune pathways. Key pharmaceutical companies such as Edesa Biotech, Allakos, Hapten Sciences, and ILiAD Biotechnologies, among others, are focusing on developing targeted therapies that address the underlying immunological mechanisms while minimizing side effects associated with long-term corticosteroid use. DelveInsight's "Allergic Contact

All 5 Releases


More Releases for Surgical

Surgical Robotics Market to Witness Huge Growth by 2031 -Auris Surgical Robotics …
Surgical Robotics Industry Analysis, according DataM Intelligence. Although data provides an overview, the research explores the hidden aspects of the sector, breaking down its intricate dynamics, charting regional dominance, spotting demand patterns, and spotting prospective breakthroughs that could influence how businesses operate in the future. Will the Surgical Robotics market emerge as the sector's next great thing? To discover the answer, look at the Surgical Robotics market analysis and projections. In-depth
Surgical Laser Market - Shaping Surgical Precision: Surgical Laser, Guiding the …
Newark, New Castle, USA - The latest report from Growth Plus Reports analyzes the production, potential applications, demand, major manufacturers, and SWOT analysis of the global Surgical Laser Market. Surgical Laser Market: https://www.growthplusreports.com/report/surgical-laser-market/9172 The Surgical Laser Market Report assists in determining the optimum distribution methods for certain products as well as possible markets for future product launches. The report also analyses the purchase and supply trends that influence the market's production strategy.
Surgical Retractor Market - Enabling Surgical Mastery: Retractors for Uncompromi …
Newark, New Castle, USA: The "Surgical Retractor Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors Surgical Retractor Market: https://www.growthplusreports.com/report/surgical-retractor-market/7658 This latest report researches the industry structure, sales,
Surgical Robots Market Hits USD 17,647.82 million by 2028 Lead By THINK Surgical …
There is a rise in the number of surgeries performed across the world. In the last 25 years, the incidence of cardiovascular diseases has increased globally. The rise in diabetic cases and lifestyle changes are leading to an increase in the number of cardiovascular surgeries and general surgeries. For instance, colorectal cancer is one of the most commonly found and lethal cancers developed in individuals due to the combined influence
Surgical Robots Market Analysis 2020 - How COVID19 Impacting Surgical Robots Ind …
Report Analyzes Surgical Robots Market Size, Share and Industry Analysis By Type (Implantable Cardioverter Surgical Robots (ICD), Transvenous ICD, External Surgical Robots) By End User (Hospitals & Clinics, Ambulatory, Schools and other Public Places) and Regional Forecast, 2019 - 2026. Get Sample Report To Know The Impact of Covid19 on this Industry at: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/surgical-robots-market-100948 Key Players: Intuitive Surgical, Medtronic, Stryker, Smith & Nephew, Zimmer Biomet, TransEnterix Surgical, Inc Verb Surgical, THINK Surgical. An
Surgical Microscope Market Size, Surgical Microscope Market Share, Surgical Micr …
The global surgical microscope market was valued at USD 610.3 million in 2017 and is estimated to grow at a CAGR of 12.5% during the forecast period 2017-2026. Request for Sample of This Research Report @ https://bit.ly/2xjcXML Top Key Players:- Carl Zeiss AG, Leica Microsystems, Takagi Corporation, Seiler Precision Microscopes, Topcon Corporation, Alltion (Wuzhou) Co. Ltd., Alcon Laboratories, Inc., Haag-Streit Surgical, Olympus Corporation, Accu-scope, Inc., Novartis AG, Danaher Corporation, Labomed Microscopes, Prescott’s Inc.,